Chengdu Olymvax Biopharmaceuticals Inc. (SHA:688319)

Market Cap	11.41B +130.6%
Revenue (ttm)	704.16M +19.6%
Net Income	22.23M +7.1%
EPS	0.05 +7.0%
Shares Out	405.71M
PE Ratio	513.16
Forward PE	156.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,192,604
Average Volume	9,200,928
Open	27.85
Previous Close	27.30
Day's Range	27.11 - 28.24
52-Week Range	12.45 - 34.68
Beta	0.51
RSI	46.75
Earnings Date	Mar 31, 2026

About SHA:688319

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was founded in 2009 and is based in Chengdu, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 463
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688319

Financial Performance

In 2025, SHA:688319's revenue was 704.16 million, an increase of 19.58% compared to the previous year's 588.86 million. Earnings were 22.23 million, an increase of 7.10%.